Amicus Therapeutics Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 16 Posts
Biotechnology Stocks Preparing A New Bullish Trend
Article By: Taki Tsaklanos Sunday, July 8, 2018 11:26 AM EDT
Biotechnology stocks look bullish, and even more bullish than ever in the last three years.
In this article: IBB, ILMN, REGN, BIIB, CELG, XBI, ARRY, FOLD, SGMO, XLRN
Read
Healthcare Investing Ideas Big And Small
Article By: Marc Lichtenfeld Monday, January 15, 2018 9:00 PM EDT
With a dire need for growth, many in the industry expect the larger biotech and pharmaceutical companies to open their wallets and acquire smaller companies with novel drugs in development.
In this article: BMY, GSK, JNJ, PFE, AVXL, IMMP, BMRN, FOLD, SGEN, MBOT
Read
Top Analysts Are Betting On These 5 Hot Stocks For 2018
Article By: TipRanks Sunday, October 8, 2017 3:36 PM EDT
Biopharma Sarepta Therapeutics is soaring right now, and top analysts are confident that this stock still has further room to grow. Analysts are predicting that Sarepta can climb by a further 29% over the next 12 months.
In this article: GVA, FOLD, AVGO, SRPT, JD
Read
Day Trading Stock Picks For This Week - Tuesday, July 25
Article By: Cory Mitchell, CMT Tuesday, July 25, 2017 8:27 AM EDT
Day trading stock picks likely to move big (up or down) during the week of July 25: HTZ, CBI, WLL, OAS, FOLD, AKS, CLF and AMD.
In this article: HTZ, CBI, WLL, OAS, FOLD, CLF, AKS, AMD Also: SPY, BAC, AAPL, NVDA, BABA, FB, MOMO
Read
Amicus Therapeutics Announces Closing Of Underwritten Offering Of Common Stock
Article By: NASDAQ GlobeNewswire Tuesday, July 18, 2017 11:18 AM EDT
Amicus Therapeutics, a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced the closing of its previously announced offering of common stock.
In this article: FOLD
Read
Small Cap Rare Disease Biotechs Jump After Peer Amicus Gets FDA Nod
Article By: The Fly Tuesday, July 11, 2017 4:14 PM EDT
Shares of small-cap biotech companies involved in rare disease cures are trading higher after peer Amicus Therapeutics announced that the FDA informed the company that it may now submit an NDA for Fabry disease treatment migalastat.
In this article: FOLD Also: INSM, XLRN, CRBP, PTCT, AGIO, IDRA, DMTX
Read
Amicus Therapeutics Stock Tumbles After FDA Setback
Article By: AO Markets Wednesday, November 30, 2016 11:52 AM EDT
Amicus Therapeutics stock tumbled on Tuesday after it had announced a major setback. The problem is that the company hoped that it could seek marketing approval for its Fabry disease drug Galafold in the coming months.
In this article: FOLD
Read
E Small Cap Best & Worst Report - November 19, 2015
Article By: E.B. Capital Markets Thursday, November 19, 2015 9:10 AM EDT
The average small cap score is 49.76 and that's below the four week moving average score of 51.79. The average small cap stock is trading -33.2% below its 52 week high, -9.57% below its 200 dma, and has 8.27 days to cover held short.
In this article: AIQ, EBS, GTS, SRI, XOXO, FOLD, AEGN, AMSG, BANR, CFNL, DCOM, DRYS, EBIX, GROW
Read
E Amicus Therapeutics, Inc. Provides FDA Update For Fabry Disease Program
Article By: Terry Chrisomalis Friday, October 2, 2015 1:38 PM EDT
Shares of Amicus Therapeutics are down 40% today after the company admitted it will not be able to file an NDA for its Fabry Disease drug Migalastat this year.
In this article: FOLD
Read
Amicus Therapeutics - All Time High
Article By: Jim Van Meerten Thursday, August 6, 2015 12:29 AM EDT
Since the Trend Spotter signaled a buy on 5/26 the stock gained 55.34%.
In this article: FOLD
Read
MEI Pharma Is Oversold And Will Recover
Article By: Scott Matusow Wednesday, April 1, 2015 12:02 PM EDT
Recently, MEI Pharma reported that its Phase II trial for Pracinostat in combination with azacitidine failed to meet its primary endpoint. However, Pracinostat has been shown to work in a 2nd line setting. With catalysts upcoming, the stock is oversold and half valued and should rally back.
In this article: MEIP, FOLD, ACAD
Read
E Shares Of Amicus Therapeutics Are Up 30% After Positive Meeting With FDA And EMA On Rare Disease Drug
Article By: Terry Chrisomalis Thursday, March 19, 2015 1:07 PM EDT
FOLD's Fabry drug migalastat receives Accelerated Approval in both U.S. and Europe.
In this article: FOLD
Read
5 Best Performing Russell 2000 Stocks Of 2014
Article By: Zacks Investment Research Tuesday, December 23, 2014 11:13 AM EDT
The Russell 2000 Index has lagged all the major benchmarks for most part of this year. As of Dec 22, the index has returned only 3.3%.
In this article: GTIV, UEIC, FLWS, SKH, AVNR, OVAS, RCPT, ACHN, TGTX, FOLD, PTX, AMRE
Read
Perceptive Advisors Continues To Buy Amicus, Likely Acquisition Soon
Article By: Scott Matusow Thursday, December 4, 2014 2:06 PM EDT
Investor Joseph Edelman leads Perceptive Advisors and since 1999 the fund has returned an annualized 30.2%. Last year, the fund returned about 48%. Edelman works with six biotech analysts to find companies with potential large gains ahead.
In this article: ACAD, FOLD, ITMN, SRPT
Read
Town Sports International And Amicus Therapeutics Buy Signals
Article By: Jim Van Meerten Wednesday, September 10, 2014 1:39 PM EDT
Today I added Town Sports International and Amicus Therapeutics to the Barchart Van Meerten Speculative portfolio for very positive price momentum. I
In this article: CLUB, FOLD
Read
Signals Overview Points Out Great Stocks
Article By: Jim Van Meerten Monday, August 25, 2014 4:18 PM EDT
Each day Barchart in a section called Signals Overview highlights some of the best and worst stocks in their technical analysis ranking system.
In this article: TA, TRT, CDZI, FOLD, DKL
Read
1 to 16 of 16 Posts